Annovis Bio Presents Buntanetap Development Update, Targets Alzheimer’s Drug Application in 2027

PUBT · 1d ago
Annovis Bio Presents Buntanetap Development Update, Targets Alzheimer’s Drug Application in 2027
  • Annovis Bio expects symptomatic data from its Phase 3 DUET-AD Alzheimer's trial in Q1 2027.
  • The approval timeline targets a symptomatic-treatment NDA in Q1 2027, followed by a disease-modifying NDA in Q1 2028.
  • DUET-AD is fully enrolled with 862 participants receiving buntanetap or placebo over 18 months.
  • The completed Phase 3 Parkinson's trial met its endpoints in the per-protocol population.
  • Cash totaled $21 million, with no debt.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief on November 14, 2026, and is solely responsible for the information contained therein.